Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment

PURPOSE: The phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) pathway controls insulin sensitivity and glucose metabolism. Hyperglycemia is one of the most common on‐target adverse effects (AEs) of PI3K/AKT inhibitors. As several PI3K and AKT inhibitors are approved by the United States Food...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dazhi, Weintraub, Michael A., Garcia, Christine, Goncalves, Marcus D., Sisk, Ann Elizabeth, Casas, Alissa, Harding, James J., Harnicar, Stephen, Drilon, Alexander, Jhaveri, Komal, Flory, James H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041081/
https://www.ncbi.nlm.nih.gov/pubmed/35212193
http://dx.doi.org/10.1002/cam4.4579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041081/
https://www.ncbi.nlm.nih.gov/pubmed/35212193
http://dx.doi.org/10.1002/cam4.4579

Ejemplares similares